Lipiarmycin inhibited the activity of deoxyribonucleic acid-dependent ribonucleic acid (RNA) polymerase in vitro. We showed that inhibition was due to interference by lipiarmycin with the activity of cr-containing molecules of RNA polymerase. Transcription by core enzyme was relatively resistant to the drug, but addition of a-led to highly drug-sensitive RNA synthesis. We isolated lipiarmycin-resistant mutants of Bacillus subtilis and characterized them genetically and biochemically. Drug-resistant mutants contained an altered RNA polymerase that was resistant to the drug in vitro. By separation and mixed reconstitution of core and a-fractions of mutant and wild-type RNA polymerase, we showed that lipiarmycin resistance in one mutant strain was a property of the core fraction. Genetic mapping experiments indicated that at least two Ipm mutants are located between loci determining rifampin resistance and streptolydigin resistance.
Lipiarmycin (Lpm), an antibiotic isolated from an Actinoplanes species, is a potent inhibitor of growth of gram-positive bacteria (2, 10) . Initial experiments with Bacillus subtilis indicated that a low concentration of the drug (1 ,ug/ml) is sufficient to block immediately the incorporation of radioactive precursors into ribonucleic acid (RNA); incorporation into protein stops after a few minutes, but incorporation into deoxyribonucleic acid (DNA) is only affected after about 40 min (2, 17) . At a much higher concentration (100 ,ug/ml) the action of the drug is less specific, causing a much more rapid shutoff of protein and DNA synthesis (17) .
Experiments with DNA-dependent RNA polymerase (nucleoside triphosphate:RNA nucleotidyl transferase; EC 2.7.7.6) purified from B. subtilis and Escherichia coli have shown that in vitro transcription is Lpm sensitive even at low concentrations (17) and that initiation of RNA synthesis rather than RNA chain elongation seems to be the drug-sensitive step (17, 21) . Whereas inhibition of transcription was reported to be strongly template dependent (17, 21) , it was uncertain whether Lpm interferes with RNA synthesis by binding preferentially to certain DNA templates or by interacting with RNA polymerase in a way that would cause inhibition to depend on the nature of the DNA. The latter might be the case if the activity of the a subunit of RNA polymerase were 73 particularly sensitive to this drug.
To test whether Lpm inhibits transcription by interaction with RNA polymerase, we sought to isolate mutant strains of B. subtilis resistant to the drug to see if such mutants contained Lpm-resistant RNA polymerase. We report here the isolation of such mutants and their initial genetic and biochemical characterization. We have identified the Lpm-sensitive element of wild-type RNA polymerase as a component of the core fraction, but have found that this sensitivity is expressed predominantly when the enzyme is in the holoenzyme form.
MATERIALS AND METHODS
Bacterial strains. Strains of B. subtilis used in this work are listed in Table 1 .
Media. Basal medium 121 and its derivatives 121A and 121B have been described (20) . L medium, Difco sporulation medium (DSM), and transformation media (SpC and SpT) were as described (18) .
Measurements of growth and sporulation. Growth of cultures was monitored by measuring changes in turbidity, using a Klett-Summerson colorimeter with a green (no. 54) filter. To test for spore formation, 1-ml samples of cultures were heated to 80°C for 10 until use. After suspension in 2 ml of buffer G (0.2 M KCI) per g of cell pellet, the cells were disrupted by sonic treatment in a jacketed vessel that allowed constant passage of ice-cold brine. The supernatant fluid from subsequent centrifugation (100,000 x g for 90 min at 2°C) was adjusted to 60% of saturation by addition of solid enzyme-grade (NH4)2SO4. The pH was adjusted by adding 5 du of 1 N NaOH per g of (NH4)2S04. After the mixture was stirred slowly for 20 min at 4°C, the precipitated proteins were collected by centrifugation at 90,000 x g for 20 min at 2°C. Pellets were suspended in buffer C (0.5 M Trishydrochloride [pH 7.91-0.05 M KCl-1 mM EDTA-0.3 mM dithiothreitol-5% glycerol), divided into small portions, and stored at -76°C. Such preparations were used routinely to test whether mutant strains contained Lpm-resistant (Lpmr) RNA polymerase activity.
To separate core and or-factor components of RNA polymerase, additional purification steps were used. The high-speed supernatant fluid of sonically treated cells was first adjusted to 35% of saturation with (NH4)2S04. The small pellet that resulted from subsequent centrifugation was discarded; the supernatant fluid of this centrifugation was adjusted to 60% of saturation as above. After suspension of the final ammonium sulfate pellet in buffer C, the extract was applied to a column of agarose (Bio-Gel A-1.5M, 200 to 400 mesh) and eluted with buffer C. The resulting Bio-Gel-purified enzyme was dialyzed against buffer C and applied to a column of diethylaminoethyl-cellulose and eluted stepwise between 0.13 and 0.24 M KCI. After concentration by precipitation with (NH4)2SO4 (60% of saturation) and suspension in a small amount of buffer C, the enzyme preparation was applied in 0.15 M KCI to a column of phosphocellulose (PC) at a flow rate of 1 columnvolume/h. After a wash with buffer C (0.15 M KCI), core enzyme was eluted stepwise between 0.25 and 0.4 M KCI. Sigma-factor activity was found in the last several protein-containing fractions of the flowthrough. In some experiments, gel filtration was omitted and diethylaminoethyl-cellulose-purified enzyme was efficiency of colony formation was 2 x 10-6 or less on such plates. Most, but not all, of the colonies that appeared were stably resistant clones. At drug concentrations greater than 30 ,ug/ml, colony formation by parent strains was less than 10-8.
Mutant strains isolated at 10 Ag of Lpm per ml were drug sensitive at higher concentrations. For example, strain LS105 was able to grow well on plates containing either 10 or 20 ,ug of drug per ml, but grew very poorly at 40
,ug/ml and not at all at 60 ,ug/ml. Acquisition of Lpm resistance did not alter the sensitivity of any of the strains to rifampin (5 ,tg/ml) or streptolydigin (40 ,ug/ml), two other antibiotics that inhibit RNA polymerase. Growth of mutants. The response to Lpm of mutant and parent strains was compared in liquid cultures of growing and sporulating cells. Addition of 2 uig of the drug per ml to vegetative cells of parent strain JAS5 led to inhibition of growth, whereas exposure of mutant strain LS105 to the same drug concentration caused only a slight reduction in the growth rate ( Fig. 1) . At a higher drug concentration (20 jAg/ml), the growth of LS105 was inhibited ( Fig. 1 ). Growth of a highly resistant mutant, LS1057, whose isolation is described below, was only slightly affected by Lpm at 20 jig/ml (Fig. 1 Interestingly, inhibition of the Lpms parent strain (JAS5) by a low concentration of Lpm was transient, as if the strain was able to become adapted to the presence of the drug. A similar result was obtained when another parent strain, 3610, was challenged with 1 ,ug of Lpm per ml (data not shown).
In vitro drug resistance. The Lpm sensitivity of DNA-dependent RNA polymerase activity was analyzed in partially purified extracts of parent and mutant strains, using as template the DNA of phage qe, a DNA whose transcription is highly dependent on the o-subunit of RNA polymerase (16) . For Lpms parent strains (JAS5, TAL, 3610, anid DR38) 0.3 to 0.5 ,ig of Lpm per ml was sufficient to inhibit transcription by 50% or more (Fig. 2) . Even at 2.5 ,ug/ml, however, synthesis corresponding to 10 to 15% residual activity was detected. Mutant strains LS105, LS117, DR100, and DR101 contained RNA polymerase activity that was inhibited less than 35% by Lpm at 0.5 ,ug/ml; at 2.5 jug/ml there remained 20 to 60% residual activity (Fig. 2) . In these experiments amounts of extract representing nearly equal RNA polymerase activities were used in comparing mutant and wild-type strains. The extracts had similar specific activities.
When RNA polymerase activity was tested with the template poly(dA-dT), a DNA whose transcription is not stimulated by a- (22) , it was clear that at least in a partially purified extract low concentrations of the drug had measurable activity in antagonizing transcription of poly(dA-dT) (Fig. 2a) . This result differs from that obtained with purified E. coli RNA polymerase (17, 21 the Lpmr extract was much less sensitive than that by the Lpm5 extract (Fig. 2a) .
The drug response of RNA polymerase activity in vitro has been confirmed by experiments with permeable whole cells. Using the coldshock toluene treatment described by Fisher et al. (3), we found that parent and mutant cells made permeable to the substrates of RNA polymerase showed the same pattern of drug sensitivity as did extracts (Fig. 3) . The template for these reactions was the endogenous B. subtilis chromosome.
Isolation of a highly resistant mutant. Since most of the spontaneous Lpmr mutants we isolated from four different parent strains showed less than total resistance in vitro, we sought derivatives that might be more resistant to the drug. Such a highly resistant mutant (LS1057) was isolated by plating about 108 cells of strain LS105 on DSM medium containing 40 ,ug of Lpm per ml. Strain LS1057 was the most resistant of the 50 clones that grew up. It formed colonies in the presence of 60 ,ug as well as 40 ug of drug per ml. In liquid culture its growth was not significantly affected by 20 ,ug of Lpm per ml, a concentration that prevented growth of its parent Lpmr strain LS105 (Fig. 1) . Assays of RNA polymerase activity in whole cells made permeable with toluene suggested that the enzyme of strain LS1057 is considerably more drug resistant than that of its parents (Fig. 3) , but extracts of strain LS1057 contained RNA polymerase activity that was no more resistant to Lpm than that of strain LS105 (data not shown).
Lpmr phenotype is due to a mutated core enzyme. RNA polymerase core enzyme and a--factor fractions were purified from Lpms and Lpmr strains by high-speed centrifugation, ammonium sulfate fractionation, agarose gel fil- tration, and chromatography on diethylaminoethyl-cellulose and PC. The last purification step separated cr and core enzyme fractions. Core enzyme has a low but measurable activity with ¢e DNA. With core enzymes from Lpms strains (3610 and JAS5) this activity was relatively resistant to Lpm (Fig. 4a) . When PC flow-through fraction containing cr-factor was added to these core enzymes, their ability to transcribe ¢4e DNA increased 5-to 10-fold (not shown). More importantly, the addition of a also caused sensitivity to Lpm to be greatly increased (Fig. 4a) . Thus, sigma-stimulated transcription of (e DNA is particularly sensitive to Lpm. In fact, the partial sensitivity of core enzyme in these experiments is probably due to small amounts of holoenzyme in our core preparations. Tjian et al. (23) have shown that core prepared by a single passage over PC contains detectable amounts of a-.
Mixed reconstitution of holoenzyme from PCpurified core and flow-through fractions from the Lpmr strain LS105 and various Lpms strains indicated that it is the core fraction of strain LS105 that is altered. Thus, the mixture of LS105 core and flow-through from either LS105 or LS3 (a Rfmr mutant) yielded holoenzyme that was as resistant to Lpm as LS105 core alone (Figure 4a core enzyme from Lpms strains with the flowthrough fraction from LS105 or LS3 produced a holoenzyme that was highly sensitive to the drug (Figure 4a) , we conclude that the lpm-105 mutation is a lesion in a gene coding for a subunit of core enzyme.
The above result suggests that the core enzyme is the target of Lpm in wild-type cells, assuming that the mechanism by which the lpm-105 mutation causes Lpm resistance is to reduce binding ofthe drug by RNA polymerase. If so, then binding of the drug is likely to interfere with binding of a or be restricted to RNA polymerase molecules containing cr.
Transcription of poly(dA-dT) by holoenzyme is Lpm sensitive. Given the above results it seems surprising that transcription of poly(dA-dT) by ammoniurm sulfate extracts of Lpms strains was sensitive to Lpm (Fig. 2a) , since transcription of this template is neither stimulated nor depressed by or. To know whether o-was responsible for the Lpm sensitivity of poly(dA-dT) transcription, we tested the effect of the drug on transcription by core and reconstituted holoenzyme (Fig. 4b) . It is clear that it is the holoenzyme form of RNA polymerase that is subject to Lpm inhibition even when poly(dA-dT) is the template. Whereas poly(dA-dT) transcription by E. coli RNA polymerase is sensitive to Lpm only at very high drug concentrations (17, 21) , this difference between the B. subtilis and E. coli enzymes cannot be attributed to any protein other than C in ourB. subtilis PC flow-through preparations, since Lpm sensitivity was also seen when pure a-was used to reconstitute holoenzyme (Fig. 4b) .
Mapping of lpm mutations. The mutations conferring Lpm' to strains LS105 and LS117 were tested for linkage to known RNA polymerase mutations (rifampin resistance [rfm] and streptolydigin resistance [std] ; see ref. 18 ) by transformation. In two-factor crosses using the DNA of LS3 (Rfmr Lpms) as donor, we found 54 and 65% linkage between rfm-3Y (rpoB3) and lpm-105 and Ipm-117, respectively. For threefactor crosses, strains LS105 and LS117 were first transformed to Rfmr by DNA from CK1 (rfm-2103), creating strains LS1051 (lpm-105 rfm-2103) and LS1171 (lpm-117 rfm-2103). DNA from these latter strains was used to transform DR10 (std-10) to Rfmr or Lpmr. Among the Rfmr transformants, 38% were Lpmr for LS1051 and 62% were Lpmr for LS1171. By analyzing the relative frequencies of Rfm' recombinant classes, we concluded that both lpm-105 and lpm-11 7 mapped between the markers rfm-2103 and std-10 (Table 3) . Analysis of Lpmr transformants was consistent with this view but not without ambiguity (Table 4) .
A tentative map for this region of the B. subtilis chromosome is presented in Fig. 5 .
The mutation (lpm-7) conferring high-level drug resistance to strain LS1057 has not been mapped. Preliminary experiments, however, indicate that this mutation is not linked by transformation to the rfm-lpm-std cluster. DISCUSSION The isolation of Lpm-resistant mutants of B. subtilis that contain a drug-resistant RNA polymerase strongly suggests that the drug inhibits transcription by interaction with the polymerizing enzyme. By mixed reconstitution of core and a-factor-containing fractions of mu- tant and wild-type RNA polymerase we have shown that it is a gene coding for a component of the core enzyme that determines drug sensitivity, suggesting that this core component is the direct target of the drug. Since mapping data establish that at least two 1pm mutations are closely linked to mutations that are very likely to reside in the gene for the 8 subunit of RNA polymerase (5, 8) , it can be expected that the p subunit is, in fact, the target of Lpm. Mutations in genes coding for other subunits of the enzyme, however, might also cause Lpm resistance.
Our finding that a-dependent transcription is particularly sensitive to Lpm suggests that the drug may act by binding to the core enzyme in a way that is antagonistic to a-function. This would occur if the binding site for the drug were identical to or impinged upon the binding site for a or if the drug only bound effectively to molecules of the enzyme that were in the holoenzyme form. Our observation that poly(dAdT) transcription by B. subtilis RNA polymerase is sensitive to low concentrations of Lpm would seem to be at odds not only with the hypothesis that the drug acts by interfering with a-activity, but with previous reports on the behavior ofE. coli RNA polymerase as well (17, 21) . Whereas B. subtilis RNA polymerase contains a subunit, 8, that accentuates strandselective transcription of middle and late genes during infection by phage SPOl (11) and for which no corresponding polypeptide has ever been detected in association with E. coli RNA polymerase, our results cannot be attributed to the presence of this subunit (Fig. 4b) . The most likely explanation of the Lpm sensitivity of poly(dA-dT) transcription is that when a-is present RNA synthesis proceeds by a a--dependent pathway, even though a-has little or no effect on the amount of RNA made. Binding of Lpm to molecules of holoenzyme might block this pathway. It is interesting to note that a sigma-dependent initiation event, the formation of an initiating dinucleotide, occurs with poly(dA-dT) as template (6) . Experiments are in progress to test whether the difference in drug sensitivity of B. subtilis and E. coli RNA polymerases resides in their respective a-or core components.
If our hypothetical mechanism of drug resistance is correct, one might expect to isolate Lpmr mutants that would fall into at least three groups: (i) strains carrying core mutations that cause reduced binding of the drug, as the mutants described here are likely to be; (ii) strains carrying mutations in the c-gene that cause this subunit to function in the presence of the drug; and (iii) strains carrying regulatory mutations causing overproduction of RNA polymerase components. A further prediction is that starting with a mutant of any one of the above classes, it should be possible to isolate more highly resistant derivatives that have secondsite mutations of the alternative types. Whereas strain LS1057 may be an example of such a case, its behavior in in vitro transcription experiments is not clear-cut (no increase in drug resistance could be detected in extracts, but a clear difference between LS1057 and its parents was observed in toluene-treated whole cells [ Fig. 3]) . Thus, whereas the second mutation of LS1057 may affect RNA polymerase directly, we cannot rule out the possibility that the mutation increases drug resistance in vivo by reducing cell permeability to the drug. If the latter explanation is correct, however, cells made permeable to nucleoside triphosphates must remain impermeable to Lpm. All the Lpmr mutants described here sporulate at 370C. In some mutant strains, however, 1pm mutations alter sporulation in one of two ways. Like rifampin and streptolydigin resistance mutations (18, 19 ; T. Leighton, J. Biol. Chem., in press), some lpm mutations cause loss of ability to sporulate (D. M. Rothstein, unpublished experiments). On the other hand, a high proportion of spontaneous Lpmr derivatives of strain DR38, a mutant that is temperature sensitive for sporulation and has a temperature-sensitive defect in sporulating cell RNA polymerase activity (15) , sporulate nearly as well as wild-type strains (D. M. Rothstein, Ph.D. thesis, Tufts University, Boston, Mass., 1977). Thus, it appears that some 1pm mutations can compensate for the ts defect in DR38, allowing sporulation to occur at high temperature. (The mutation of strain DR100 is one such example.)
The mechanism proposed for Lpm action suggests that the drug can be used to test the role of a-during infection of B. subtilis by various bacteriophages. Our initial observations are that phages 4e, SPOl, and 4105 are dependent on Lpm-sensitive host functions during the first part of the infection cycle (M. Osburne and A. L. Sonenshein, manuscript in preparation). SPOl is known to induce sequentially polypeptides that bind to the host RNA polymerase (4). Pero and co-workers have shown that at least some of these polypeptides are responsible for promoting middle and late RNA synthesis in vitro (11, 12) . We have tested the Lpm sensitivity of middle and late RNA polymerases purified and provided by G. Lee and J. Pero and found them to be entirely Lpm resistant (M. Osburne and A. L. Sonenshein, manuscript in preparation). These results could mean that unmodified host holoenzyme is required early after infection, but that thereafter the activity of the host a-factor is dispensable.
Infection with phage PBS2 is thought to be independent of host RNA polymerase since it is resistant to rifampin even when the drug is added to host cells before infection (1, 13, 14) . PBS2 infection was sensitive to Lpm, however, during early periods of the developmental cycle (Osburne and Sonenshein, manuscript in preparation). This result could imply that an as yet unidentified early RNA polymerase (which may be a phage-coded enzyme or a phage-modifled host enzyme) is sensitive to the drug. The phage-coded "late polymerase" (1) is resistant to Lpm in vitro (S. Clark, personal communication).
An interesting aspect of the effect of Lpm on growing cells is that genotypically drug-sensitive cells can become adapted to low concentrations of the drug (1 to 2 ,ug/ml). Additional experiments indicate that this adaptation is not due to inactivation of the drug; the cells become phenotypically drug resistant (S. Voynow and A. L. Sonenshein, unpublished experiments). An attractive explanation for this phenomenon is that cells challenged with a low dose of Lpm channel their residual RNA and protein synthetic capacity toward the production of unusually large amounts of cr, core, or RNA polymerase holoenzyme.
